ExeVir Bio SRL
1.8 FTEThe score of ExeVir Bio shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -77 % Total assets -80 % Headcount (avg FTE) -82 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ExeVir Bio's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jun 2025
- Year ended 31 Dec 2023filed on 27 Jun 2024
- Year ended 31 Dec 2022filed on 16 Jun 2023
- Year ended 31 Dec 2021filed on 09 Jun 2022
ExeVir Bio's financial analysis
- Solvency97.7%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ExeVir Bio
ExeVir Bio's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0750.495.334
- VAT number
- BE0750495334
- Peppol
- Registered · 0208:0750495334 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Jul 2020
- Registered office
- 9052 Ghent
- Size
- Micro · 1.8 FTE
- Latest accounts
- 2025 · filed on 03 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
ExeVir Bio (SRL) has been based in Ghent since 2020, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €1.94m and equity of €3.67m; its revenue is not published. With 1.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 97.7%, above the median of its sector (61.7%).
Companies similar to ExeVir Bio
Companies in the same business, of comparable size and area, outside its group.
- Genflow Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.74m
- Tanai Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.87m
- XomeXBio Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.50m
- Wishbone Research and experimental development on natural sciences and engineering Flémalle · balance sheet €3.39m
- Ipratech Research and experimental development on natural sciences and engineering Charleroi · balance sheet €4.29m
- BIO-Sourcing Research and experimental development on natural sciences and engineering Liège · balance sheet €6.59m
- Amyl Therapeutics Research and experimental development on natural sciences and engineering Liège · balance sheet €7.02m
- Bioxodes Research and experimental development on natural sciences and engineering Charleroi · balance sheet €7.68m
Frequently asked questions about ExeVir Bio
What is the revenue of ExeVir Bio?
ExeVir Bio files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ExeVir Bio?
In Belgium, the VAT number is the company number prefixed with BE: BE0750495334 for ExeVir Bio, if the company is VAT-registered. Its company number (CBE) is 0750.495.334.
Where is the registered office of ExeVir Bio?
According to the CBE register, the registered office of ExeVir Bio is in 9052 Ghent.
What is the equity of ExeVir Bio?
At the close of the 2025 financial year, the equity of ExeVir Bio amounts to 3,672,552 €, a solvency of 97.7% of total assets.
How many people work at ExeVir Bio?
1.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ExeVir Bio?
The register lists 5 active mandates at ExeVir Bio. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ExeVir Bio
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →